Elan posts ISEQ gains
Shares in Elan jumped almost 4% this morning after it said the latest trials of its multiple sclerosis drug Tysabri on people who have the disease showed significant positive effects on their quality of life.
Elan were up 45c to €12.05.
The Business Hub
Newsletter
News and analysis on business, money and jobs from Munster and beyond by our expert team of business writers.





